Details for New Drug Application (NDA): 211094
✉ Email this page to a colleague
The generic ingredient in DASATINIB is dasatinib. There are fourteen drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the dasatinib profile page.
Summary for 211094
| Tradename: | DASATINIB |
| Applicant: | Teva Pharms Usa |
| Ingredient: | dasatinib |
| Patents: | 0 |
Pharmacology for NDA: 211094
| Mechanism of Action | Cytochrome P450 3A4 Inhibitors Protein Kinase Inhibitors |
Medical Subject Heading (MeSH) Categories for 211094
Suppliers and Packaging for NDA: 211094
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| DASATINIB | dasatinib | TABLET;ORAL | 211094 | ANDA | Teva Pharmaceuticals, Inc. | 0480-3523 | 0480-3523-56 | 30 TABLET, FILM COATED in 1 BOTTLE (0480-3523-56) |
| DASATINIB | dasatinib | TABLET;ORAL | 211094 | ANDA | Teva Pharmaceuticals, Inc. | 0480-3524 | 0480-3524-56 | 30 TABLET, FILM COATED in 1 BOTTLE (0480-3524-56) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 20MG | ||||
| Approval Date: | Aug 27, 2025 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 50MG | ||||
| Approval Date: | Aug 27, 2025 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 70MG | ||||
| Approval Date: | Aug 27, 2025 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
